Sahar Ghanavati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sahar Ghanavati has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arsalan Salari
Department of Cardiology, School of Medicine, Cardiovascular Diseases Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Elham Ramezanzade
Razi Clinical Research Development Center, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Mahsa Khedmatbin Dana
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Milad Bahram Mirzaei
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Salman Nikfarjam
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Seyed Aboozar Fakhr-Mousavi
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, GuilanUniversity of Medical Sciences, Rasht, Iran
1 shared publication
Latest Publications
- 17 December 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15, e32291
Serum copeptin level in contrast-induced nephropathy
Introduction: The incidence of contrast-induced nephropathy (CIN) among patients who have undergone coronary angiography is about 10%-15%. According to the recent studies, copeptin might be a potential biomarker to predict the outcomes of adverse cardiac and renal events. Objectives: This study aimed to assess the association between serum copeptin levels and CIN. Patients and Methods: In this cross-sectional study a total of 75 candidates of percutaneous coronary intervention (PCI) or angiography were enrolled. A 12-lead ECG was recorded. The blood sample test was taken daily to identify changes in serum creatinine levels. CIN was defined as a 25% or 44 µmol/L increase in serum creatine in comparison to baseline or an increase in serum creatinine level ≥ 0.3 mg/dL (24.6 µmol/L) within 48-72 hours after contrast medium administration. IBM SPSS version 26.0 was used for all statistical analyses at a level of statistical significance of P<0.05. Results: The 48-hour follow-ups after the procedure revealed increased blood urea nitrogen levels in 8% and increased serum creatinine levels in 5.33% of patients. There was no relation between CIN development and serum copeptin. Our result showed no statistically significant association of serum copeptin levels with serum creatinine elevation and glomerular filtration rate (GFR) changes. Although, copeptin levels at admission, as well as hyperlipidemia, were independent predictors of serum creatinine increases and GFR decrement. Conclusion: In conclusion, the serum copeptin level could be introduced as a simple prognostic biomarker for serum creatinine elevation and GFR decrement after contrast medium administration during coronary angiography or PCI.
- 17 December 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15, e32291
Serum copeptin level in contrast-induced nephropathy
Introduction: The incidence of contrast-induced nephropathy (CIN) among patients who have undergone coronary angiography is about 10%-15%. According to the recent studies, copeptin might be a potential biomarker to predict the outcomes of adverse cardiac and renal events. Objectives: This study aimed to assess the association between serum copeptin levels and CIN. Patients and Methods: In this cross-sectional study a total of 75 candidates of percutaneous coronary intervention (PCI) or angiography were enrolled. A 12-lead ECG was recorded. The blood sample test was taken daily to identify changes in serum creatinine levels. CIN was defined as a 25% or 44 µmol/L increase in serum creatine in comparison to baseline or an increase in serum creatinine level ≥ 0.3 mg/dL (24.6 µmol/L) within 48-72 hours after contrast medium administration. IBM SPSS version 26.0 was used for all statistical analyses at a level of statistical significance of P<0.05. Results: The 48-hour follow-ups after the procedure revealed increased blood urea nitrogen levels in 8% and increased serum creatinine levels in 5.33% of patients. There was no relation between CIN development and serum copeptin. Our result showed no statistically significant association of serum copeptin levels with serum creatinine elevation and glomerular filtration rate (GFR) changes. Although, copeptin levels at admission, as well as hyperlipidemia, were independent predictors of serum creatinine increases and GFR decrement. Conclusion: In conclusion, the serum copeptin level could be introduced as a simple prognostic biomarker for serum creatinine elevation and GFR decrement after contrast medium administration during coronary angiography or PCI.